drugset
drugset / Trial / NCT01413568

Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies

NCT01413568 ↗

Phase 1/2 Completed 38 enrolled Polyphor Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

Determine the safety and tolerability of POL6326 when used as a single mobilization agent.

Timeline

Start
2012-04
Primary completion
2015-11
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Balixafortide Peptide — Intravenous

Indications

B-cell chronic lymphocytic leukemia acute myeloid leukemia adult acute lymphoblastic leukemia chronic myeloid leukemia myelodysplastic syndrome plasma cell myeloma